Autosomal-dominant Alzheimer's disease: A review and proposal for the prevention of Alzheimer's disease

Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA. .
Alzheimer's Research and Therapy (Impact Factor: 3.98). 01/2011; 3(1):1. DOI: 10.1186/alzrt59
Source: PubMed


Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and molecular studies of autosomal-dominant Alzheimer's disease, highlighting the similarities and differences between the dominantly inherited form of Alzheimer's disease and the more common sporadic form of Alzheimer's disease. Current developments in autosomal-dominant Alzheimer's disease are presented, including the international Dominantly Inherited Alzheimer Network and this network's initiative for clinical trials. Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention.

Download full-text


Available from: Bart De Strooper
  • Source
    • "c o m / l o ca t e / n e u a g i n g (measured using task free functional magnetic resonance imaging [MRI]), neuronal destruction (reflected by elevation of CSF tau), and increased rates of brain atrophy (quantified using serial MRI) in vulnerable regions. Importantly, all these events are thought to precede the development of cognitive decline and symptoms by a decade or more in the case of Ab accumulation, and several years in the case of excess atrophy rates, opening a potential window for secondary prevention studies aiming to prevent or delay the time to the development of cognitive impairment (Bateman et al., 2011; Desikan et al., 2012; Sperling et al., 2011b, 2014). Formalized and revised in a series of highly influential articles (Jack et al., 2010, 2011b, 2012, 2013), current hypotheses predict not only the sequence of changes occurring during the prodromal phase of Alzheimer's disease (Young et al., 2014) but also the trajectory of biomarker changes in this sequence, suggesting that the rate at which each biomarker becomes abnormal occurs in a sigmoidal fashion, that is, showing initial rapid acceleration followed by a period of linear increase, before decelerating toward a steady state as the biomarker in question becomes abnormal (Caroli and Frisoni, 2010; Sabuncu et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rates of atrophy measured from serial MRI precedes symptom onset in Alzheimer’s disease, and may be a useful outcome measures for prodromal clinical trials. Appropriate trial design requires a detailed understanding of the relationships between β-amyloid load and accumulation, and rate of brain change at this stage of the disease. 52 healthy individuals (72.3±6.9 years) from AIBL had serial (0, 18m, 36m) MRI, (0, 18m) PiB PET and clinical data. We calculated rates of whole brain and hippocampal atrophy, ventricular enlargement, amyloid accumulation, and cognitive decline. Over three years, rates of whole brain atrophy (p<0.001), left and right hippocampal atrophy (p=0.001, p=0.023) and ventricular expansion (p<0.001) were associated with baseline β-amyloid load. Whole brain atrophy rates were also independently associated with β-amyloid accumulation over the first 18 months (p=0.003). Acceleration of hippocampal atrophy rate was associated with baseline β-amyloid load across the cohort (p<0.05). We provide evidence that rates of atrophy are associated with both baseline β-amyloid load and accumulation, and that there is pre-symptomatic, amyloid-mediated acceleration of hippocampal atrophy. Clinical trials using rate of hippocampal atrophy as an outcome measure should not assume linear decline in the pre-symptomatic phase.
    Full-text · Article · Oct 2015 · Neurobiology of Aging
  • Source
    • "An emerging view is that therapeutic success may only be possible with intervention very early in the disease course. This has motivated the development of treatment trials specifically for FAD, which offers the possibility of treating individuals at a preclinical disease stage (Bateman et al., 2011; Reiman et al., 2010). Furthermore, the young age of patients with FAD, which typically manifests in the 30se50s, means that comorbidities such as atherosclerotic cerebrovascular "
    [Show abstract] [Hide abstract]
    ABSTRACT: Familial Alzheimer's disease (FAD) treatment trials raise interest in the variable occurrence of cerebral amyloid angiopathy (CAA); an emerging important factor in amyloid-modifying therapy. Previous pathological studies reported particularly severe CAA with postcodon 200 PSEN1 mutations and amyloid beta coding domain APP mutations. As CAA may manifest as white matter hyperintensities (WMH) on magnetic resonance imaging, particularly posteriorly, we investigated WMH in 52 symptomatic FAD patients for associations with mutation position. WMH were visually rated in 39 PSEN1 (18 precodon 200); 13 APP mutation carriers and 25 healthy controls. Ten PSEN1 mutation carriers (5 precodon 200) had postmortem examination. Increased WMH were observed in the PSEN1 postcodon 200 group and in the single APP patient with an amyloid beta coding domain (p.Ala692Gly, Flemish) mutation. WMH burden on MRI correlated with severity of CAA and cotton wool plaques in several areas. The precodon 200 group had younger ages at onset, decreased axonal density and/or integrity, and a greater T-lymphocytic response in occipital deep white matter. Mutation site contributes to the phenotypic and pathological heterogeneity witnessed in FAD.
    Full-text · Article · Sep 2015 · Neurobiology of aging
  • Source
    • "The majority of AD cases (>95%) are non-Mendelian forms with a typical age of onset of 65 years or older; therefore, these types of AD are also occasionally referred to as late-onset AD. In contrast, fAD accounts for less than 1–5% of cases and is caused by mutations in one of three definite genes [3]. Age of onset is frequently before 65 years with these patients oftentimes referred to as early onset AD [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Most forms of Alzheimer's disease (AD) are sporadic (sAD) or inherited in a non-Mendelian fashion, and less than 1% of cases are autosomal-dominant. Forms of sAD do not exhibit familial aggregation and are characterized by complex genetic and environmental interactions. Recently, the expansion of genomic methodologies, in association with substantially larger combined cohorts, has resulted in various genome-wide association studies that have identified several novel genetic associations of AD. Currently, the most effective methods for establishing the diagnosis of AD are defined by multi-modal pathways, starting with clinical and neuropsychological assessment, cerebrospinal fluid (CSF) analysis, and brain-imaging procedures, all of which have significant cost- and access-to-care barriers. Consequently, research efforts have focused on the development and validation of non-invasive and generalizable blood-based biomarkers. Among the modalities conceptualized by the systems biology paradigm and utilized in the "exploratory biomarker discovery arena", proteome analysis has received the most attention. However, metabolomics, lipidomics, transcriptomics, and epigenomics have recently become key modalities in the search for AD biomarkers. Interestingly, biomarker changes for familial AD (fAD), in many but not all cases, seem similar to those for sAD. The integration of neurogenetics with systems biology/physiology-based strategies and high-throughput technologies for molecular profiling is expected to help identify the causes, mechanisms, and biomarkers associated with the various forms of AD. Moreover, in order to hypothesize the dynamic trajectories of biomarkers through disease stages and elucidate the mechanisms of biomarker alterations, updated and more sophisticated theoretical models have been proposed for both sAD and fAD.
    Full-text · Article · Sep 2015 · Journal of Alzheimer's disease: JAD
Show more